These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27687958)

  • 1. Treatment of diabetes: Crossing to the other side.
    Skliros NP; Vlachopoulos C; Tousoulis D
    Hellenic J Cardiol; 2016; 57(5):304-310. PubMed ID: 27687958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of cardiovascular outcome trials in type 2 diabetes.
    Cypryk K; Małecki P
    Endokrynol Pol; 2018; 69(4):. PubMed ID: 30209802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes medications and cardiovascular outcome trials: Lessons learned.
    Patel KV; de Albuquerque Rocha N; McGuire DK
    Cleve Clin J Med; 2017 Oct; 84(10):759-767. PubMed ID: 28985176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs for type 2 diabetes mellitus: the imperative for cardiovascular outcome assessment.
    Gore MO; McGuire DK
    Diab Vasc Dis Res; 2012 Apr; 9(2):85-8. PubMed ID: 22496441
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?
    John M; Gopalakrishnan Unnikrishnan A; Kalra S; Nair T
    Indian Heart J; 2016; 68(4):564-71. PubMed ID: 27543483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.
    Panicker GK; Karnad DR; Salvi V; Kothari S
    J Assoc Physicians India; 2012 Jan; 60():56-61. PubMed ID: 22715547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular safety of therapies for type 2 diabetes.
    Gupta P; White WB
    Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes.
    Chilton RJ; Dungan KM; Shubrook JH; Umpierrez GE
    Prim Care Diabetes; 2020 Jun; 14(3):193-212. PubMed ID: 31704161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular trials and diabetes treatments: a regulatory maze.
    Matthews DR
    Diab Vasc Dis Res; 2012 Apr; 9(2):83-4. PubMed ID: 22419242
    [No Abstract]   [Full Text] [Related]  

  • 11. [Oral antidiabetic drugs. How to begin and combine without cardiovascular risk].
    Duarte R
    Rev Port Cardiol; 2013 Apr; 32 Suppl 1():15-24. PubMed ID: 23721975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular safety evaluation in the development of new drugs for diabetes mellitus.
    Menon V; Lincoff AM
    Circulation; 2014 Jun; 129(25):2705-13. PubMed ID: 24958753
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiovascular safety of anti-diabetic drugs.
    Kumar R; Kerins DM; Walther T
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):32-43. PubMed ID: 27533060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular safety of type 2 diabetes medications: Review of existing literature and clinical implications.
    Paredes S; Matta-Coelho C; Monteiro AM; Brás A; Marques O; Alves M; Ribeiro L
    Hormones (Athens); 2016 Apr; 15(2):170-185. PubMed ID: 27376421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidiabetic Drugs as Antihypertensives: New Data on the Horizon.
    Mamakou V; Eleftheriadou I; Katsiki N; Makrilakis K; Tsioufis K; Tentolouris N
    Curr Vasc Pharmacol; 2017; 16(1):70-78. PubMed ID: 29032756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to use type 2 diabetes meds to lower CV disease risk.
    Gotfried R
    J Fam Pract; 2019 Nov; 68(9):494;498;500;504. PubMed ID: 31725134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of antidiabetic therapy on the risk of cardiovascular diseases and their complications in patients with type 2 diabetes mellitus].
    Ametov AS; P'ianykh OP; Chernikova NA
    Ter Arkh; 2010; 82(8):71-5. PubMed ID: 20873250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of cardiovascular outcome trials with injectable antidiabetic agents.
    Pratley RE
    J Diabetes; 2018 Oct; 10(10):801-803. PubMed ID: 29971941
    [No Abstract]   [Full Text] [Related]  

  • 19. Current perspectives on cardiovascular outcome trials in diabetes.
    Schnell O; Rydén L; Standl E; Ceriello A;
    Cardiovasc Diabetol; 2016 Oct; 15(1):139. PubMed ID: 27716274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations for design and data analysis of noninferiority/superiority cardiovascular trials.
    Quan H; Li M; Zhao PL; Cho M; Zhang J; Wu Y
    J Biopharm Stat; 2013; 23(1):239-60. PubMed ID: 23331234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.